MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Compugen Ltd

Slēgts

1.55 -8.28

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.53

Max

1.64

Galvenie mērījumi

By Trading Economics

Ienākumi

-1.1M

-7.2M

Pārdošana

813K

2.3M

P/E

Sektora vidējais

60.333

39.564

Peļņas marža

-314.405

Darbinieki

74

EBITDA

-912K

-8.4M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+215.38% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 5. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-526M

161M

Iepriekšējā atvēršanas cena

9.83

Iepriekšējā slēgšanas cena

1.55

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Compugen Ltd Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 11. jūl. 22:19 UTC

Iegādes, apvienošanās, pārņemšana

FCC Approves U.S. Cellular Sale to T-Mobile

2025. g. 11. jūl. 17:28 UTC

Galvenie tirgus virzītāji

SharpLink Gaming Gains on Ethereum Purchase

2025. g. 11. jūl. 16:57 UTC

Peļņas

BASF Cuts Outlook on Global Economy Uncertainty

2025. g. 11. jūl. 21:45 UTC

Tirgus saruna

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

2025. g. 11. jūl. 19:46 UTC

Iegādes, apvienošanās, pārņemšana

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

2025. g. 11. jūl. 19:45 UTC

Tirgus saruna

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

2025. g. 11. jūl. 19:05 UTC

Tirgus saruna

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

2025. g. 11. jūl. 18:18 UTC

Tirgus saruna

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

2025. g. 11. jūl. 17:35 UTC

Tirgus saruna

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

2025. g. 11. jūl. 17:26 UTC

Tirgus saruna

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

2025. g. 11. jūl. 16:53 UTC

Tirgus saruna

Crude Futures Add to Early Gains -- Market Talk

2025. g. 11. jūl. 16:42 UTC

Peļņas

BASF Cuts Outlook on Global Economic Uncertainty

2025. g. 11. jūl. 16:08 UTC

Tirgus saruna

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

2025. g. 11. jūl. 16:05 UTC

Peļņas

BASF Will Publish Half-Year Results on July 30

2025. g. 11. jūl. 16:04 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 11. jūl. 16:04 UTC

Tirgus saruna

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

2025. g. 11. jūl. 16:03 UTC

Peļņas

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

2025. g. 11. jūl. 16:02 UTC

Peļņas

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

2025. g. 11. jūl. 16:01 UTC

Peļņas

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

2025. g. 11. jūl. 16:00 UTC

Peļņas

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

2025. g. 11. jūl. 15:59 UTC

Peļņas

BASF Cuts 2025 Earnings View

2025. g. 11. jūl. 15:58 UTC

Peļņas

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

2025. g. 11. jūl. 15:57 UTC

Peļņas

BASF 2Q EBIT Before Special Items EUR810M

2025. g. 11. jūl. 15:54 UTC

Peļņas

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

2025. g. 11. jūl. 15:54 UTC

Peļņas

BASF 2Q Sales Fell 2.1% on Year

2025. g. 11. jūl. 15:53 UTC

Peļņas

BASF 2Q Sales EUR15.77B

2025. g. 11. jūl. 15:52 UTC

Peļņas

BASF: This Was in Line With Consensus Estimates

2025. g. 11. jūl. 15:52 UTC

Peļņas

BASF 2Q Ebitda Before Special Items EUR1.77B

2025. g. 11. jūl. 15:49 UTC

Peļņas

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

2025. g. 11. jūl. 15:41 UTC

Tirgus saruna

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Salīdzinājums

Cenas izmaiņa

Compugen Ltd Prognoze

Cenas mērķis

By TipRanks

215.38% augšup

Prognoze 12 mēnešiem

Vidējais 5.33 USD  215.38%

Augstākais 10 USD

Zemākais 2 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Compugen Ltd — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

3

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

1.25 / 1.48Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Very Strong Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.